Thrombolysis in acute stroke: ongoing challenges based on a tertiary hospital audit and comparisons with other Australian studies
Alex H. T. Lau A B , Graham Hall A , Ian A. Scott A and Marie Williams AA Department of Internal Medicine, Princess Alexandra Hospital, 199 Ipswich Road, Woolloongabba, Qld 4102, Australia. Email: graham.hall2@health.qld.gov.au; Ian.Scott@health.qld.gov.au; Marie.Williams@health.qld.gov.au
B Corresponding author. Email: alex.lau@health.qld.gov.au
Australian Health Review 40(1) 43-53 https://doi.org/10.1071/AH14167
Submitted: 30 September 2014 Accepted: 20 April 2015 Published: 29 June 2015
Abstract
Objective Intravenous thrombolysis with tissue plasminogen activator (tPA) improves patient outcomes in acute ischaemic stroke. Because its benefit is time-dependant, treatment delays must be minimised. The aim of the present study was to review patient characteristics, timeliness of tPA delivery and clinical outcome in patients receiving t-PA in a tertiary hospital stroke unit in Queensland, and to compare the findings with those of other Australian studies.
Methods The present study was a retrospective study conducted between 1 January 2010 and 31 December 2012. Information was collected regarding demographics, stroke characteristics, timeliness of tPA delivery, clinical outcome, safety outcome and protocol deviation.
Results Of 490 patients admitted with ischaemic stroke, 57 (11.6%) received tPA. Compared with other studies, the patients in the present study had more severe stroke (median National Institutes of Health Stroke Scale (NIHSS) score), more cardioembolic strokes and more patients receiving tPA between 3 and 4.5 h of symptoms onset. Median symptom onset to treatment time was 175 min and median door to needle time was 97 min. At 3 months, 21.1% of patients had died and 41.5% had a favourable outcome (modified Rankin scale ≤2). Symptomatic intracerebral haemorrhage occurred in 5.3% of patients and protocol deviations occurred in 21.1%. Overall, delivery and outcomes of tPA at the Princess Alexandra Hospital were comparable to those reported in other Australian studies of usual care. Several challenges and strategies for optimal thrombolysis were identified, with supporting evidence from selected Australian sites.
Conclusion The proportion of eligible stroke patients who receive tPA in a timely manner remains less than ideal at our centre. More accurate patient selection and reductions in treatment delays serve as targets for quality improvement efforts that have broad applicability.
What is known about the topic? Stroke unit care and tPA thrombolysis are two proven strategies to improve outcome in patients with ischaemic stroke. Although the stroke unit is gaining momentum of growth in Australia (especially in Queensland), little improvement has been achieved in thrombolysis rate and timeliness of treatment delivery, and little is known about the service delivery in Queensland because there are no published data.
What does this paper add? This paper provides an extensive review of thrombolysis treatment in a tertiary Queensland hospital, adding to the understanding of treatment implementation. It also provides a complete and comprehensive review of treatment delay (including emergency department referral time and computed tomography to needle time, which have not been reported in other Australian studies), and a template for data collection to review treatment delay and outcome measurement in detail. It also compares findings with peer Australian studies (this has not been reported previously) and summarises potential strategies that could be adopted systemically.
What are the implications for practitioners? Delivery of thrombolysis treatment in a timely manner remains a significant challenge to stroke physicians. All stroke units are encouraged to prospectively collect thrombolysis data in the format adopted in the present study for purposes of peer comparisons and shared learning.
References
[1] Hankey GJ. Transient ischaemic attacks and stroke. Med J Aust 2000; 172 394–400.| 1:STN:280:DC%2BD3c3pvFGgsA%3D%3D&md5=f5dd48fbbefceca6d06ee08c64a0a864CAS | 10840494PubMed |
[2] The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333 1581–8.
| Tissue plasminogen activator for acute ischemic stroke. Crossref | GoogleScholarGoogle Scholar | 7477192PubMed |
[3] The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363 768–74.
| Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.Crossref | GoogleScholarGoogle Scholar | 15016487PubMed |
[4] Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; 4 CD000213
| 19821269PubMed |
[5] Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, Cohen G. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379 2364–72.
| Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XnsVGjsb4%3D&md5=e83277cd424a6ba5dd1f88edb0f8a839CAS | 22632907PubMed |
[6] Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Keulkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007; 369 275–82.
| Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD2sXpvV2gtw%3D%3D&md5=dbbba1b5805727fe1d05d5c38afd366cCAS | 17258667PubMed |
[7] Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, Roine RO, Toni D, Lees KR.. Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372 1303–9.
| Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXht1ejurbE&md5=42da660bb1a93f67afe0e7b35f885b51CAS | 18790527PubMed |
[8] Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003; 34 2847–50.
| Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD3sXpt1Krurk%3D&md5=520503874d0bb4b95df1d84241c1248fCAS | 14605319PubMed |
[9] Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359 1317–29.
| Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD1cXhtFGqu77E&md5=25db1af92dcf6b66dc198d7c722aaa80CAS | 18815396PubMed |
[10] National Stroke Foundation. Clinical guidelines for stroke management. Melbourne: National Stroke Foundation; 2010.
[11] National Stroke Foundation and the Stroke Society of Australasia. The implementation of intravenous tissue plasminogen activator in acute ischaemic stroke: a scientific position statement from the National Stroke Foundation and the Stroke Society of Australasia. Intern Med J 2009; 39 317–24.
| The implementation of intravenous tissue plasminogen activator in acute ischaemic stroke: a scientific position statement from the National Stroke Foundation and the Stroke Society of Australasia.Crossref | GoogleScholarGoogle Scholar | 19545242PubMed |
[12] Szoeke CE, Parsons MW, Butcher KS, Baird TA, Mitchell PJ, Fox SE, David SM. Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital. Med J Aust 2003; 178 324–8.
| 12670274PubMed |
[13] Bray JE, Coughlan K, Bladin C. Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital. Intern Med J 2006; 36 483–8.
| Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BD28Xot1Cnsrg%3D&md5=2dc75388105773e236441128c98bf36eCAS | 16866650PubMed |
[14] Batmanian JJ, Lam M, Matthews C, Finckh A, Duffy M, Wright R, Brew BJ, Markus R. A protocol-driven model for the rapid initiation of stroke thrombolysis in the emergency department. Med J Aust 2007; 187 567–70.
| 18021045PubMed |
[15] Leyden JM, Chong WK, Kleinig T, Lee A, Field JB, Jannes J. A population-based study of thrombolysis for acute stroke in South Australia. Med J Aust 2011; 194 111–15.
| 21299483PubMed |
[16] Simpson MA, Dewey HM, Churilov L, Ahmed N, Bladin CF, Schultz D, Markus R, Sturm JW, Levi CR, Blacker DJ, Jannes J, Lindley RI, Parsons MW. Thrombolysis for acute stroke in Australia: outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002–2008). Med J Aust 2010; 193 439–43.
| 20955119PubMed |
[17] National Stroke Foundation. National stroke audit: acute services clinical audit report. Melbourne: National Stroke Foundation; 2013.
[18] National Stroke Foundation. National stroke audit: organisational report acute service. Melbourne: National Stroke Foundation; 2007.
[19] National Stroke Foundation. National stroke audit acute services: organisational survey report. Melbourne: National Stroke Foundation; 2013.
[20] Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337 1521–6.
| Classification and natural history of clinically identifiable subtypes of cerebral infarction.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaK3M3mtVamsw%3D%3D&md5=2d5bf335b540c1a505103463b9cdef4dCAS | 1675378PubMed |
[21] National Institutes of Health, National Institute of Neurological Disorders and Stroke. Stroke scale. 2013. Available at: http://www.ninds.nih.gov/doctors/NIH_Stroke_Scalepdf [verified 3 May 2015].
[22] van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19 604–7.
| Interobserver agreement for the assessment of handicap in stroke patients.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DyaL1c3gsFCgtQ%3D%3D&md5=2fab7d4040332688b1622a82e86a0d54CAS | 3363593PubMed |
[23] Quain DA, Parsons MW, Loudfoot AR, Spratt NJ, Evans MK, Russell ML, Royan AT, Moore AG, Miteff F, Hullick CJ, Attia J, McElduff P, Levi CR. Improving access to acute stroke therapies: a controlled trial of organised pre-hospital and emergency care. Med J Aust 2008; 189 429–33.
| 18928434PubMed |
[24] O’Brien W, Crimmins D, Donaldson W, Risti R, Clarke TA, Whyte S. FASTER (Face, Arm, Speech, Time, Emergency Response): experience of Central Coast Stroke Services implementation of a pre-hospital notification system for expedient management of acute stroke. J Clin Neurosci 2012; 19 241–5.
| FASTER (Face, Arm, Speech, Time, Emergency Response): experience of Central Coast Stroke Services implementation of a pre-hospital notification system for expedient management of acute stroke.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC387ns1Sntg%3D%3D&md5=6767741082dd2e24090ce78b79a78277CAS | 22118794PubMed |
[25] Tai YJ, Weir L, Hand P, Davis S, Yan B. Does a ‘code stroke’ rapid access protocol decrease door-to-needle time for thrombolysis? Intern Med J 2012; 42 1316–24.
| Does a ‘code stroke’ rapid access protocol decrease door-to-needle time for thrombolysis?Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC38XhvVOrtrfE&md5=fb700efef33f66ebe25c1c1f4b3d039fCAS | 22212180PubMed |
[26] Meretoja A, Weir L, Ugalde M, Yassi N, Yan B, Hand P, Truesdale M, Davis SM, Campbell BCV. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology 2013; 81 1071–6.
| Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXhsVymu77L&md5=df919afd7c073b67cbb61236b3b3b404CAS | 23946303PubMed |
[27] National Institute of Neurological Disorders and Stroke. NINDS stroke information page. 2010. Available at: http://www.ninds.nih.gov/disorders/stroke/stroke.htm [verified June 2014].
[28] Mosley I, Nicol M, Donnan G, Patrick I, Dewey H. Stroke symptoms and the decision to call for an ambulance. Stroke 2007; 38 361–6.
| Stroke symptoms and the decision to call for an ambulance.Crossref | GoogleScholarGoogle Scholar | 17204685PubMed |
[29] Bray JE, Mosley I, Bailey M, Barger B, Bladin C. Stroke public awareness campaigns have increased ambulance dispatches for stroke in Melbourne, Australia. Stroke 2011; 42 2154–7.
| Stroke public awareness campaigns have increased ambulance dispatches for stroke in Melbourne, Australia.Crossref | GoogleScholarGoogle Scholar | 21757668PubMed |
[30] Audebert HJ, Saver JL, Starkman S, Lees KR, Endres M. Prehospital stroke care: new prospects for treatment and clinical research. Neurology 2013; 81 501–8.
| Prehospital stroke care: new prospects for treatment and clinical research.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC3sXht1SksbvL&md5=3724151f48991b79238c13cb216ee699CAS | 23897876PubMed |
[31] Ebinger M, Winter B, Wendt M, Weber JE, Waldschmidt C, Rozanski M, Kunz A, Koch P, Kellner PA, Gierhake D, Villringer K, Fiebach JB, Grittner U, Hartmann A, Mackert B-M, Endrew M, Audebert HJ. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. JAMA 2014; 311 1622–31.
| Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial.Crossref | GoogleScholarGoogle Scholar | 1:CAS:528:DC%2BC2cXhsFems73I&md5=36cac7123ca0a8415d28ebc89b118e08CAS | 24756512PubMed |
[32] Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 2012; 79 306–13.
| Reducing in-hospital delay to 20 minutes in stroke thrombolysis.Crossref | GoogleScholarGoogle Scholar | 22622858PubMed |
[33] Lindsberg PJ, Happola O, Kallela M, Valanne L, Kuisma M, Kaste M. Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment. Neurology 2006; 67 334–6.
| Door to thrombolysis: ER reorganization and reduced delays to acute stroke treatment.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BD28vktFOitg%3D%3D&md5=02ce4e5ca2c05de238be51e49c412c05CAS | 16864834PubMed |
[34] Mishra NK, Albers GW, Davis SM, Donnan GA, Furlan AJ, Hacke W, Lees KR. Mismatch-based delayed thrombolysis: a meta-analysis. Stroke 2010; 41 e25–33.
| Mismatch-based delayed thrombolysis: a meta-analysis.Crossref | GoogleScholarGoogle Scholar | 19926836PubMed |
[35] Wintermark M, Sanelli PC, Albers GW, Bello JA, Derdeyn CP, Hetts SW, Johnson MH, Kidwell CS, Lev MH, Liebeskind DS, Rowley HA, Schaefer PW, Sunshine JL, Zaharchuk G, Meltzer CC. Imaging recommendations for acute stroke and transient ischemic attack patients: a joint statement by the American Society of Neuroradiology, the American College of Radiology and the Society of NeuroInterventional Surgery. J Am Coll Radiol 2013; 10 828–32.
| Imaging recommendations for acute stroke and transient ischemic attack patients: a joint statement by the American Society of Neuroradiology, the American College of Radiology and the Society of NeuroInterventional Surgery.Crossref | GoogleScholarGoogle Scholar | 23948676PubMed |
[36] Tai YJ, Yan B. Minimising time to treatment: targeted strategies to minimise time to thrombolysis for acute ischaemic stroke. Intern Med J 2013; 43 1176–82.
| Minimising time to treatment: targeted strategies to minimise time to thrombolysis for acute ischaemic stroke.Crossref | GoogleScholarGoogle Scholar | 1:STN:280:DC%2BC3snpsVyqug%3D%3D&md5=8c392e04e4d0a6a0e76ac552ebbb5e5eCAS | 23734983PubMed |
[37] Chakraborty S, Ross J, Hogan MJ, Dowlatshahi D, Stotts G. Beating the Clock: Time Delays to Thrombolytic Therapy with Advanced Imaging and Impact of Optimized Workflow. J Stroke Cerebrovascular Dis 2015; in press
